immunotherapy

1:26
EBMT guidelines CAR-T education & guidelines for nurses
Rose Ellard
1:34
CAR-T: symptoms and their assessment
Rose Ellard
8:08
CAR T-cell therapy; guidelines for nurses
Orla Stewart
1:16
CAR-T treatment journey and the role of the nurse
Rose Ellard
0:35
The importance of patient monitoring post-CAR-T treatment
Rose Ellard
2:43
Progression of multiple myeloma novel therapies with Prof. Nagler
Arnon Nagler
2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt
1:48
Is the lack of ICU space an issue for CAR-T therapy?
Victoria Metaxa
1:35
CAR-T therapy: ethical challenges
Victoria Metaxa
2:09
May the EuroCAR-T Force be with you: improving CAR-T patient care
Victoria Metaxa
1:29
Further progression for CAR T-cell therapy?
Paolo Strati
2:04
Emerging therapies in AML: why patients should be optimistic
Naval Daver
3:08
Venetoclax-IDH inhibitor combination therapy for AML
Naval Daver
4:09
ADCs for AML: potential alternatives to gemtuzumab ozogamicin
Naval Daver
2:07
ADCs for AML: gemtuzumab ozogamicin
Naval Daver
2:57
Venetoclax and FLT3 inhibitor combination therapy for AML
Naval Daver
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals